<DOC>
	<DOCNO>NCT00262886</DOCNO>
	<brief_summary>RATIONALE : A peripheral stem cell transplant bone marrow transplant brother sister may effective treatment kidney cancer . PURPOSE : This phase II trial study well donor peripheral stem cell bone marrow transplant work treat patient relapsed refractory metastatic kidney cancer .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Bone Marrow Transplant Treating Patients With Relapsed Refractory Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy nonmyeloablative sibling allogeneic peripheral blood stem cell transplantation patient relapse refractory metastatic renal cell carcinoma . - Determine toxic effect regimen patient . OUTLINE : This pilot study . - Conditioning regimen : Patients receive cyclophosphamide IV day -7 -6 fludarabine IV day -5 -1 . Patients receive 5/6-mismatched cell also receive anti-thymocyte globulin IV day -5 -3 . - Allogeneic peripheral blood stem cell ( PBSC ) infusion : Patients undergo allogeneic PBSC bone marrow transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive oral mycophenolate mofetil twice daily day 0-30 . Patients receive tacrolimus IV continuously orally twice daily begin day -2 continue day 44-100 absence GVHD . - Donor lymphocyte infusion : Patients partial complete T-cell chimerism receive 3 donor lymphocyte infusion absence GVHD progressive disease . After completion study treatment , patient evaluate periodically 3 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma Relapsed refractory disease Tumor amenable complete surgical resection No bone metastases No untreated brain metastasis Measurable disease Available sibling donor HLAidentical mismatch single HLA locus ( i.e. , 6/6 5/6 match HLAA , B , DR locus ) PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 3 mg/dL Renal Creatinine &lt; 2 mg/dL No untreated hypercalcemia Cardiovascular LVEF ≥ 40 % Pulmonary DLCO ≥ 40 % Other Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test HIV1 2 negative No uncontrolled infection No active malignancy except basal skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : At least 15 day since prior treatment renal cell carcinoma No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>